Acorda Therapeutics Inc., of Hawthrone, N.Y., promoted Anthony Caggiano to vice president of preclinical development.
Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed A. Collier Smyth to its board of directors.
Gene Network Sciences Inc., of Cambridge, Mass., named Eric Schadt as co-chairman of its scientific advisory board.
GeneNews Ltd., of Toronto, appointed David Sable to its board.
Geron Corp., of Menlo Park, Calif., appointed Karin Eastham to its board of directors.
Infinity Pharmaceuticals Inc., of Cambridge, Mass., promoted John J. Keilty to vice president of information technology and informatics, and Joseph F. McPherson to vice president of facilities and operations.
Inovio Biomedical Corp., of San Diego, named Ng Tee Khiang to its board of directors.
Lux Innovate Ltd., of Edinburgh, UK, appointed Alison (Ali) Clark chief financial officer.
MacroGenics Inc., of Rockville, Md., appointed Eric Risser vice president of business development.
Microbia, Inc., of Lexington, Mass., appointed Mike Doyle senior vice president and general manager of nutrition ingredients.
Novexel, of Paris, appointed Karen Bush to its scientific advisory board.
Otonomy Inc., of San Diego, named Rick Friedman, Jeffrey Harris, Allen Ryan, Stephan Heller, Charles Liberman, Christopher Post and Alec Salt to its scientific advisory board.
RXi Pharmaceuticals Corp., of Worcester, Mass., named Ramani Varanasi vice president of business development; promoted Stephen DiPalma to executive vice president of business operations and chief financial officer; and named Joanne Kamens as senior director.
Valeant Pharmaceuticals International, of Aliso Viejo, Calif., appointed Steve Stefano to its board.
Yongye Biotechnology International Inc., of Beijing, named Sam Yu chief financial officer.